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PGenetics and Coronary Artery Disease
Association of the Trp719Arg Polymorphism in
Kinesin-Like Protein 6 With Myocardial Infarction
and Coronary Heart Disease in 2 Prospective Trials
The CARE and WOSCOPS Trials
Olga A. Iakoubova, MD, PHD,* Carmen H. Tong, BS,* Charles M. Rowland, MS,*
Todd G. Kirchgessner, PHD,† Bradford A. Young, PHD,* Andre R. Arellano, BS,*
Dov Shiffman, PHD,* Marc S. Sabatine, MD, MPH,‡ Hannia Campos, PHD,§
Christopher J. Packard, DSC, Marc A. Pfeffer, MD, PHD,‡ Thomas J. White, PHD,*
Eugene Braunwald, MD, FACC,‡ James Shepherd, PHD, James J. Devlin, PHD,*
Frank M. Sacks, MD‡§
Alameda, California; Princeton, New Jersey; Boston, Massachusetts; and Glasgow, United Kingdom
Objectives We asked whether 35 genetic polymorphisms, previously found to be associated with cardiovascular disease,
were associated with myocardial infarction (MI) in the CARE (Cholesterol and Recurrent Events) trial and with
coronary heart disease (CHD) in the WOSCOPS (West of Scotland Coronary Prevention Study) trial and whether
the risk associated with these polymorphisms could be reduced by pravastatin treatment.
Background Identification of genetic polymorphisms associated with CHD may improve assessment of CHD risk and under-
standing of disease pathophysiology.
Methods We tested the association between genotype and recurrent MI in the CARE study and between genotype and
primary CHD in the WOSCOPS trial using regression models that adjusted for conventional risk factors: Cox pro-
portional hazards models for the CARE study and conditional logistic regression models for a nested case-control
study of the WOSCOPS trial.
Results We found that Trp719Arg (rs20455) in KIF6 was associated with coronary events. KIF6 encodes kinesin-like pro-
tein 6, a member of the molecular motor superfamily. In placebo-treated patients, carriers of the KIF6 719Arg
allele (59.4% of the CARE trial cohort) had a hazard ratio of 1.50 (95% confidence interval [CI] 1.05 to 2.15) in
the CARE trial and an odds ratio of 1.55 (95% CI 1.14 to 2.09) in the WOSCOPS trial. Among carriers, the abso-
lute risk reduction by pravastatin was 4.89% (95% CI 1.81% to 7.97%) in the CARE trial and 5.49% (95% CI
3.52% to 7.46%) in the WOSCOPS trial.
Conclusions In both the CARE and the WOSCOPS trials, carriers of the KIF6 719Arg allele had an increased risk of coronary
events, and pravastatin treatment substantially reduced that risk. (J Am Coll Cardiol 2008;51:435–43) © 2008
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.057C
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purrent algorithms used for assessing risk of coronary heart
isease (CHD) events are based on established clinical risk
actors, yet these algorithms fail to predict many CHD
vents (1,2). Because genetics influences predisposition to
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edical School, Boston, Massachusetts; §Harvard School of Public Health, Boston,
assachusetts; and the University of Glasgow and Royal Infirmary, Glasgow, United
ingdom. Supported by research grants from Bristol-Myers Squibb Pharmaceutical
esearch Institute (to Drs. Sacks, Braunwald, Shepherd, and Packard). Genotypingi
nd statistical analysis funded by Celera.
Manuscript received May 8, 2007; accepted May 23, 2007.HD, evaluating genetic polymorphisms that are associated
ith risk of CHD may help to improve CHD risk assess-
ent (3,4). Studies that investigate the association between
HD and genetic polymorphisms may test polymorphisms
n candidate genes, which provide biologic plausibility to
ny observed association. An alternative approach is to test
olymorphisms in an unbiased collection of genes (5).
See page 456
As the technology for genotyping polymorphisms has
mproved, the number of polymorphisms reported to be
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creased; however, many of these
associations are not confirmed in
subsequent studies (6). Confir-
mation of associations between
genetic polymorphisms and CHD
can be difficult to achieve for a
variety of reasons. The typically
modest risk for CHD associated
with each genetic polymorphism
can lead to false-positive associa-
tions in initial studies or to false-
negative associations in confirma-
tion studies. Additionally, the
case-control design of an initial
study can affect subsequent confir-
mation, because unanticipated bi-
ases in the selection of subjects for
ase-control studies can lead to spurious associations. Thus,
olymorphisms reported to be associated with CHD should be
urther investigated in multiple studies, including prospective
tudies, which may avoid some of the inherent bias of case-
ontrol studies.
We selected 35 polymorphisms, which had been associ-
ted with cardiovascular disease in previous studies, for
urther investigation. Ten of these polymorphisms are in 9
andidate genes and have been reported to be associated
ith cardiovascular disease or intermediate phenotypes in 2
tudies. Four of these 10 polymorphisms are in genes related
o hemostasis: rs1126643 in ITGA2 (integrin alpha 2) has
een associated with nonfatal myocardial infarction (MI) in
ounger patients (7,8); rs1866389 in THBS4 (throm-
ospondin 4) with premature MI (9,10); rs1799768 in
ERPINE1 (plasminogen activator inhibitor-1) with MI
nd with high plasma plasminogen activator inhibitor-1
ctivity (11,12); and rs1799963 in F2 (coagulation factor II)
ith MI in young women (13,14). Two of the 10 polymor-
hisms are in genes related to hypertension: a 278-basepair
nsertion– deletion polymorphism in ACE (angiotensin
-converting enzyme) has been associated with MI (15,16);
nd rs5186 in AGTR1 (angiotensin II receptor type 1), with
ardiovascular risk independent of blood pressure (17,18).
he remaining 4 of these 10 polymorphisms are in genes
nvolved in vascular biology: rs1041981 in LTA (lympho-
oxin alpha) has been associated with MI (19,20);
s3025058 in MMP3 (matrix metallopeptidase-3) with pro-
ression of coronary atherosclerosis (21,22); rs429358, the
4 polymorphism in APOE (apolipoprotein E), with CHD
23,24); and rs405509 in the APOE promoter with in-
reased risk of MI (25) and coronary artery disease (23). The
ther 25 of the 35 polymorphisms had been previously found
o be associated with MI in a case-control study that tested
utative functional single nucleotide polymorphisms (SNPs)
resent in an unbiased collection of noncandidate genes (26).
In the present study, we asked if these 35 polymorphisms
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
DNA  deoxyribonucleic
acid
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
OR  odds ratio
SNP  single nucleotide
polymorphismere associated with MI in the placebo arm of the CARE aCholesterol and Recurrent Events) study and with CHD in
he placebo arm of the WOSCOPS (West of Scotland
oronary Prevention Study) trial and if the risk associated
ith these polymorphisms could be reduced by pravastatin
reatment.
ethods
tudy design. We conducted genetic association studies in
opulations derived from 2 prospective trials that assessed
he effect of pravastatin in the prevention of MI and CHD:
he CARE and WOSCOPS trials. The inclusion criteria for
he CARE study, a secondary prevention trial, and the
OSCOPS, a primary prevention trial, have been de-
cribed elsewhere (27–29).
The CARE study included 3,847 Caucasian patients, and
he present study comprised 2,913 Caucasian patients who
rovided deidentified deoxyribonucleic acid (DNA) for
enetic studies. We used a composite end point of con-
rmed fatal or nonfatal MI to focus on the genetics of MI
nonfatal MI constituted 86.7% of the events in this
omposite end point). The DNA was collected approxi-
ately 1.5 years after the start of the CARE trial. There-
ore, the proportion of patients with fatal MI was higher in
hose who did not provide DNA than in those who did
rovide DNA; however, there was no significant difference
or the end point of the present genetic study (fatal or
onfatal MI) between those who provided DNA and those
ho did not (30). The CARE trial genetic cohort was
estricted to Caucasian patients, because the number of
on-Caucasian patients (7.3% of the CARE trial popula-
ion) did not provide sufficient power for a separate analysis.
The present genetic study of the WOSCOPS trial was
erived from a previously described prospective nested
ase-control study, which included all of the 580 on-trial
HD events from the WOSCOPS cohort as case subjects
nd 1,160 control subjects matched to case subjects by age
nd smoking (29). The present genetic study of the
OSCOPS trial included all patients in the nested case-
ontrol study for whom sufficient DNA was available for
enotype analysis: 481 case and 1,086 control subjects.
ecause the control subjects had been matched to case
ubjects for age and current smoking status, the present
enetic study used the same CHD end point as that
eported in the prospective nested case-control study (death
rom coronary heart disease, nonfatal MI, or revasculariza-
ion procedures). The baseline characteristics for patients
ncluded in these genetic studies of CARE and WOSCOPS
re presented in Table 1. All patients enrolled in CARE and
OSCOPS provided written informed consent. The
ARE study was approved by the institutional review
oards of the Brigham and Women’s Hospital and all
articipating centers. The WOSCOPS study was approved
y the ethics committees of the University of Glasgow and
ll participating health boards.
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January 29, 2008:435–43 KIF6 Trp719Arg in the CARE and WOSCOPS Trialsenetic analysis. Genotypes were determined using mul-
iplexed polymerase chain reaction-based amplification of
enomic DNA followed by multiplexed allele detection
sing oligonucleotide ligation as described by Iannone et al.
31) (Online Appendix). Primer sequences are available
pon request. This multiplex panel was initially intended to
est 10 polymorphisms in 9 candidate genes (Table 2) that
thers had previously reported to be associated with cardio-
ascular disease in 2 studies. We investigated the 278-
asepair insertion–deletion polymorphism in ACE using an
ssay for an SNP (rs4344) reported to be in strong linkage
isequilibrium with this insertion–deletion polymorphism
32). Because the multiplex technology could accommodate
5 SNP assays in a single panel, we included 25 assays for
utative functional SNPs that had been found to be asso-
iated with disease in primary or subgroup analyses of a
ingle case-control study of MI, study 1 in Shiffman et al.
26). Most of these 25 SNPs were not in typical cardiovas-
ular disease candidate genes.
To test for association between CHD and other SNPs
hat may be in linkage disequilibrium with the KIF6
rp719Arg SNP, we selected 27 tagging SNPs, including
rp719Arg, in the regions flanking the Trp719Arg SNP
sing pairwise tagging in Tagger (33) as implemented in
aploview (34) (Online Appendix).
tatistical analysis. All reported p values are 2-sided.
ifferences between baseline characteristics of patients were
ssessed by t tests (continuous variables) or by chi-square
aseline Characteristics of Patients Genotyped for 35 Polymorphis
Table 1 Baseline Characteristics of Patients Genotyped for 35
Characteristic
CARE
On-Trial MI No On-
Patients, n 244 2,4
Men, n (%) 211 (86.5) 2,138 (86
Age, mean (SD), yrs 58.8 (9.8) 58.5 (9.3
BMI, mean (SD), kg/m2 28.0 (4.8) 27.4 (4.2
Smoking
Current 65 (26.6) 383 (15
Former 133 (54.5) 1,568 (63
Never 46 (18.9) 520 (21
History of diabetes 50 (20.5) 294 (11
History of hypertension 113 (46.3) 1,013 (41
Low-density lipoprotein cholesterol, mg/dl
Mean (SD) 141.3 (14.7) 138.9 (14
Median (range) 141.0 (115.0–175.0) 138.0 (10
High-density lipoprotein cholesterol, mg/dl
Mean (SD) 38.5 (9.1) 38.8 (8.8
Median (range) 36.8 (23.0–68.0) 37.0 (20
Total cholesterol, mg/dl
Mean (SD) 211.5 (16.7) 209.0 (17
Median (range) 214.5 (170.5–239.5) 209.5 (15
Triglycerides, mg/dl
Mean (SD) 157.9 (54.9) 157.0 (60
Median (range) 147.8 (54.0–337.0) 146.5 (43
Case and control subjects were matched for age (in 2-year age groups) and smoking (current vs
BMI  body mass index; CARE  Cholesterol And Recurrent Events study; MI  myocardial infaests (discrete variables). We assessed deviation from Iardy-Weinberg expectations using an exact test in the
ARE trial cohort and in the control patients of the
OSCOPS trial (35). The power to detect significant
ssociations with disease in the CARE and WOSCOPS
rials for each of the 35 genetic polymorphisms was esti-
ated by simulation (Online Appendix) and is shown in
able 1 of the Online Appendix.
Cox proportional hazards models in the CARE trial and
onditional logistic regression models in the WOSCOPS
rial were used to assess the association of genotype with
ncident disease in the placebo arms (Wald tests) and were
lso used to assess the effect of pravastatin compared with
lacebo in subgroups defined by genotypes. Likelihood ratio
ests were used to evaluate potential interactions between
enotype and each conventional risk factor in separate
egression models that included an interaction term between
he risk factor and genotype.
Absolute risk reduction was estimated in the CARE trial
t 5 years of follow-up using Kaplan-Meier estimates of
I-free survival of subgroups defined by KIF6 genotype.
bsolute risk and absolute risk reduction in the
OSCOPS trial was projected for the first 4.9 years of
ollow-up using estimates of the genotype frequencies, an
stimate that assumed that the outcome and treatment
rm-specific genotype frequencies of subjects included in
he nested case-control study were equal to the correspond-
ng treatment arm-specific genotype frequencies in the
OSCOPS trial cohort. The SAS version 9 software (SAS
orphisms
WOSCOPS
I p Value Case Control p Value
481 1,080
0.98 481 (100) 1,080 (100) *
0.66 56.4 (5.1) 56.2 (5.2) *
0.083 26.0 (3.2) 25.6 (3.2) 0.036
0.001 *
260 (54.1) 587 (54.5)
141 (29.3) 306 (28.4)
80 (16.6) 185 (17.2)
0.001 10 (2.1) 13 (1.2) 0.19
0.11 108 (22.5) 170 (15.8) 0.002
0.01 194.0 (17.6) 191.5 (17.1) 0.008
9.5) 191.4 (156.6–250.4) 188.5 (164.3–248.5)
0.70 41.5 (8.7) 44.2 (9.6) 0.001
0) 40.0 (21.2–70.3) 43.2 (23.1–127.8)
0.03 273.6 (23.6) 271.5 (22.2) 0.09
6.5) 271.7 (229.1–364.5) 268.8 (224.3–369.3)
0.82 174.6 (74.0) 163.4 (68.1) 0.005
.5) 161.6 (53.1–482.7) 146.1 (44.3–491.6)
rrent); all were men.
WOSCOPS  West of Scotland Coronary Prevention Study.ms
Polym
Trial M
71
.5)
)
)
.5)
.5)
.0)
.9)
.0)
.6)
0.5–17
)
.0–89.
.3)
9.0–24
.6)
.0–349nstitute, Cary, North Carolina) was used for all regression
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ival. We used the Fisher method (36) of combining p
alues to assess the evidence for association from the
ombined CARE and WOSCOPS trials. In this method,
nder the null hypothesis of no association, the statistic S
2 (ln [p1]  ln [p2]) and has a chi-square distribution
ith 4 degrees of freedom, where p1 and p2 are the p values
rom 2 degrees of freedom genotypic tests of association in
he CARE and WOSCOPS trials, respectively. We then
pplied a Bonferroni correction to the combined p value of
ach SNP to adjust for the multiple hypothesis tests
ssociation of 35 Polymorphisms With MI in CARE and CHD in WO
Table 2 Association of 35 Polymorphisms With MI in CARE and
Symbol Name SNP (Alias)
THBS4 Thrombospondin 4 rs1866389 (1186G
ACE Angiotensin I-converting enzyme rs4344 (I/D 278bp)
ITGA2 Integrin alpha 2 rs1126643 (C807T
APOE Apolipoprotein E rs429358 (3932T/C
AGTR1 Angiotensin II receptor type 1 rs5186 (A1166C)
LTA Lymphotoxin alpha rs1041981 (804C/
APOE Apolipoprotein E rs405509 (219T)
MMP3 Matrix metallopeptidase- 3 rs3025058 (1171
SERPINE1 Serpin peptidase inhibitor clade E
member 1
rs1799768 (4G/5G
F2 Coagulation factor II rs1799963 (20210
ROS1 Proto-oncogene c-ros-1 protein rs529038
BRE TNFRSF1A modulator rs1506536
GALNTL4 GalNAc-transferase rs901550
AKAP13 A kinase (PRKA) anchor protein 13 rs7162168
BDNF Brain-derived neurotropic factor rs6265
CR2 Complement component receptor 2 rs17615
CALCOCO2 Nuclear domain 10 protein rs1422645
IL12A Interleukin 12A rs2243131
ALDH4A1 Aldehyde dehydrogenase 4A1 rs2230709
LILRA4 Leukocyte immunoglobulin-like
receptor subfamily A member 4
rs2241384
WDR55 WD repeat domain 55 rs2286394
PPP4R1L Protein phosphatase 4, regulatory
subunit 1-like
rs614507
GIPR Gastric inhibitory polypeptide receptor rs1800437
KIF6 Kinesin family member 6 rs20455
MTRR Methionine synthase reductase rs1801394
ACAA1 Acetyl-coenzyme A acyltransferase 1 rs156265
LRRC25 Leucine-rich repeat–containing 25 rs6512265
R3HDM1 R3H domain-containing 1 rs961360
ACTR1B Centractin beta rs3474
LOC646871 Hypothetical LOC646871 rs3736919
ARL5C ADP-ribosylation factor–like 5C rs593772
LTK Leukocyte tyrosine kinase rs35932273
KCNQ4 Potassium voltage-gated channel rs34287852
LGALS14 Lectin, galactoside-binding, soluble, 14 rs35541195
IQCC IQ motif-containing C rs12032332
All of the gene symbols, gene names, and rs numbers are from National Center for Biotechnolog
OSCOPS trial. ‡Association between genotype and disease in Cox proportional hazards mode
ombined p value. Polymorphisms previously reported to be associated with cardiovascular disea
CHD  coronary heart disease; SNP  single nucleotide polymorphism; other abbreviations aserformed. CEstimates of absolute risk reduction and differences in
bsolute risk reduction were evaluated for statistical signif-
cance in the CARE trial by assuming the difference in the
stimate divided by its standard error approximates a stan-
ard normal distribution under the null hypothesis and by
onte Carlo simulation (100,000 iterations) in the
OSCOPS trial.
esults
ssociation with coronary events. In this genetic study of
S
in WOSCOPS
Minor Allele
Frequency† p Value‡ p Value§
CARE WOSCOPS CARE WOSCOPS Combined
0.22 0.22 0.034 0.825 0.1273
0.45 0.48 0.938 0.738 0.9469
0.40 0.40 0.986 0.166 0.4605
0.14 0.19 0.943 0.337 0.6825
0.30 0.30 0.285 0.474 0.4056
0.33 0.37 0.072 0.937 0.2496
0.49 0.46 0.234 0.897 0.5376
A) 0.50 0.49 0.862 0.940 0.9806
0.47 0.445 0.692 0.929 0.9267
0.02 0.01 0.852 0.394 0.7022
0.26 0.26 0.437 0.249 0.3507
0.49 0.50 0.463 0.833 0.7530
0.26 0.24 0.231 0.144 0.1463
0.36 0.36 0.773 0.998 0.9717
0.18 0.20 0.599 0.383 0.5671
0.32 0.31 0.481 0.417 0.5227
0.29 0.31 0.044 0.660 0.1328
0.16 0.18 0.722 0.415 0.6607
0.15 0.14 0.231 0.785 0.4914
0.16 0.17 0.023 0.713 0.0849
0.23 0.21 0.331 0.973 0.6868
0.27 0.27 0.279 0.532 0.4316
0.19 0.17 0.476 0.692 0.6948
0.36 0.34 0.029 0.004 0.0012
0.46 0.44 0.223 0.249 0.2162
0.15 0.15 0.905 0.576 0.8609
0.34 0.34 0.398 0.872 0.7140
0.18 0.09 0.624 0.309 0.5104
0.28 0.28 0.830 0.434 0.7284
0.46 0.47 0.284 0.287 0.2855
0.10 0.09 0.747 0.002 0.0093
0.03 0.03 0.925 0.177 0.4609
0.25 0.26 0.449 0.344 0.4430
0.13 0.11 0.615 0.243 0.4336
0.06 0.06 0.939 0.777 0.9697
36 unless noted otherwise. †Based on the cohort for the CARE trial and the control group for the
) or conditional logistic regression model (WOSCOPS); 2-degrees-of-freedom Wald test. §Fisher
studies.
1.SCOP
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January 29, 2008:435–43 KIF6 Trp719Arg in the CARE and WOSCOPS Trialsorphisms (Table 2). The genotype distributions for these
olymorphisms were all in accord with Hardy-Weinberg
xpectations (p  0.05) after Bonferroni correction for
esting 35 polymorphisms.
Four SNPs (in KIF6, THBS4, CALCOCO2, and LILRA4)
ere associated with MI in the placebo arm of the CARE trial
nd 2 SNPs (in KIF6 and ARL5C) were associated with CHD
n the placebo arm of the WOSCOPS trial (Table 2). The
NPs in KIF6 (p 0.001) and ARL5C (p 0.009) remained
ignificantly associated with disease after combining the evi-
ence for association from both the CARE and the
OSCOPS trials; however, only the KIF6 association re-
ained significant (p  0.04) after applying a Bonferroni
ultiple testing correction to the combined p values of the 35
NPs tested in the present study.
The KIF6 SNP (rs20455) is a Trp719Arg polymorphism
n the gene encoding kinesin-like protein 6, a member of
he superfamily of molecular motors that are involved in
ntracellular transport (37). This gene was not an a priori
andidate gene for CHD; the association between the KIF6
rp719Arg polymorphism and CHD was identified in an
nvestigation of polymorphisms in an unbiased collection of
enes. In the placebo arm of the CARE trial, carriers of the
IF6 719Arg allele had a hazard ratio (HR) for recurrent
I of 1.50 (95% confidence interval [CI] 1.05 to 2.15)
Table 3) in a model adjusted for age, gender, smoking,
istory of hypertension, history of diabetes, body mass
ndex, low-density lipoprotein cholesterol (LDL-C), and
igh-density lipoprotein cholesterol (HDL-C). This HR
or the 719Arg allele was similar to that of some of the
onventional risk factors tested in the CARE trial (Fig. 1).
n the placebo arm of the WOSCOPS trial, we found that
arriers of the KIF6 719Arg allele had an odds ratio (OR)
or CHD of 1.55 (95% CI 1.14 to 2.09) (Table 3) in a
ssoociation of KIF6 Trp719Arg with MI and CHD in the Placebo A
Table 3 Assoociation of KIF6 Trp719Arg with MI and CHD in th
Study Genotype
On-Trial
MI* Total* HR
CARE Arg/Arg 16 155 1.33
Arg/Trp 82 636 1.63
Arg/Arg 
Arg/Trp
98 791 1.57
Trp/Trp 44 542 1.00
Case* Control* OR
WOSCOPS Arg/Arg 35 59 1.49
Arg/Trp 137 204 1.61
Arg/Arg 
Arg/Trp
172 263 1.59
Trp/Trp 104 256 1.00
Number of patients. †Adjusted for gender, age (continuous), current versus noncurrent smoking, h
holesterol level (LDL-C; continuous), and baseline high-density lipoprotein cholesterol level (HDL
current versus noncurrent); all were men. §Matched for age and smoking and adjusted for history
aseline HDL-C level (continuous).
CI  confidence interval; HR  hazard ratio; OR  odds ratio; ref  reference group; other abbodel adjusted for history of hypertension, history ofiabetes, body mass index, LDL-C, and HDL-C (case and
ontrol subjects were matched for age and smoking status).
The genotype frequencies for KIF6 Trp719Arg were 40.6%,
6.5%, and 12.8%, for Trp/Trp, Arg/Trp, and Arg/Arg,
espectively, in the CARE trial cohort. In the WOSCOPS
rial control group, the frequencies were 44.2%, 43.6%, and
2.2%, respectively. The KIF6 Trp719Arg SNP was not
ssociated with any covariates used for adjustment (p  0.13),
or did we observe any consistent interaction between geno-
ype and the covariates used for adjustment in the CARE and
OSCOPS trials (data not presented).
f the CARE and WOSCOPS Trials
cebo Arms of the CARE and WOSCOPS Trials
Unadjusted Adjusted†
95% CI p Value HR 95% CI p Value
0.75–2.35 0.33 1.33 0.75–2.36 0.33
1.13–2.35 0.009 1.54 1.07–2.23 0.02
1.10–2.25 0.01 1.50 1.05–2.15 0.03
ref 1.00 ref
Matched‡ Adjusted§
95% CI p Value OR 95% CI p Value
0.92–2.40 0.10 1.48 0.91–2.41 0.11
1.18–2.21 0.003 1.56 1.14–2.15 0.006
1.18–2.14 0.003 1.55 1.14–2.09 0.005
ref 1.00 ref
f hypertension, history of diabetes, body mass index (continuous), baseline low-density lipoprotein
tinuous). ‡Case and control subjects were matched for age (in 2-year age groups) and smoking
rtension, history of diabetes, body mass index (continuous), baseline LDL-C level (continuous), and
ns as in Tables 1 and 2.
Figure 1 Adjusted Hazard Ratios for
Myocardial Infarction in the CARE Study
Comparison of the KIF6 719Arg risk allele and conventional risk factors in the
CARE study. Hazard ratios were adjusted for age, gender, smoking, baseline
low-density lipoprotein cholesterol (LDL-C) level, baseline high-density lipopro-
tein cholesterol (HDL-C) level, history of diabetes, history of hypertension, and
body mass index (BMI). The 719Trp homozygote was the reference group for
719Arg carriers. The 95% confidence intervals are shown.rms o
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KIF6 Trp719Arg in the CARE and WOSCOPS Trials January 29, 2008:435–43The Trp719Arg SNP is located on human chromosome
at position 39,433,056 and corresponds to the first
ucleotide of codon 719 in the full-length transcript
M_145027 (National Center for Biotechnology Informa-
ion SNP database, build 36.1). To explore associations
etween disease and SNPs that might be in linkage disequi-
ibrium with KIF6 Trp719Arg, we genotyped 26 other
NPs in the regions flanking the Trp719Arg SNP. We
ound that no SNP or haplotype in the KIF6 region was
ore significantly associated with both recurrent MI in the
ARE trial and with CHD in the WOSCOPS trial than
he KIF6 Trp719Arg SNP alone (Online Appendix).
We have previously reported that the 94Asn allele of the
ene FCAR on chromosome 19 was associated with MI in
he CARE trial and with CHD in the WOSCOPS trial
30). The risk associated with the KIF6 SNP seems to be
ndependent of that associated with the FCAR SNP, be-
ause the risk estimates for carriers of the KIF6 risk allele
ere essentially unchanged after adjustment for FCAR
sp92Asn and traditional risk factors: In the CARE trial
he HR for MI was 1.52 (95% CI 1.06 to 2.17); in the
OSCOPS trial the OR for CHD was 1.55 (95% CI 1.14
o 2.10). There was no indication of an interaction between
IF6 Trp719Arg and FCAR Asp92Asn (p  0.48 in the
ARE trial; p  0.98 in the WOSCOPS trial).
None of the 10 polymorphisms previously reported to be
ssociated with cardiovascular disease in multiple studies
as associated with CHD in the placebo arm of the
OSCOPS trial, and only the Ala387Pro SNP in THBS4
encoding thrombospondin 4) was associated with recurrent
I in the placebo arm of the CARE trial (Table 4).
ompared with THBS4 Ala387 homozygotes, homozy-
otes for 387Pro had a hazard ratio for MI of 2.07 (95% CI
.16 to 3.67) (Table 4). For 5 of these 10 polymorphisms (in
HBS4, ITGA2, MMP3, SERPINE1, and F2), the power
o detect association was greater than 80% in both the
ARE and the WOSCOPS trials. For the polymorphism
n LTA the power was 62% in the CARE trial and 72% in
ssociation of the THBS4 Ala387Pro SNP With MI and CHD in the
Table 4 Association of the THBS4 Ala387Pro SNP With MI and
Study Genotype
Unadjusted
HR 95% CI
CARE Pro/Pro 2.12 1.20–3.74
Pro/Ala 1.19 0.83–1.70
Ala/Ala 1.00 ref
Matched†
OR 95% CI
WOSCOPS Pro/Pro 1.11 0.56–2.22
Pro/Ala 1.10 0.80–1.52
Ala/Ala 1.00 ref
Adjusted for gender, age (continuous), current versus noncurrent smoking (except in the WOSCO
continuous), and baseline HDL-C level (continuous). †Case and control subjects were matched for
moking and adjusted for history of hypertension, history of diabetes, body mass index (continuou
Abbreviations as in Tables 1 to 3.he WOSCOPS trial. The power to detect association was r60% in both studies for the other 4 SNPs. The power to
etect association with disease for all the polymorphisms
tudied is shown in Table 1 of the Online Appendix.
IF6 Trp719Arg and the effect of pravastatin on MI and
HD. Because the KIF6 Trp719Arg SNP was associated
ith both recurrent MI in the CARE trial and CHD in the
OSCOPS trial, we asked whether carriers of the KIF6
19Arg risk allele benefited from pravastatin treatment. In the
ARE trial, pravastatin treatment reduced the relative risk of
I by 37% among carriers of the 719Arg risk allele (adjusted
R 0.63, 95% CI 0.46 to 0.87) (Table 5), and among carriers
n the WOSCOPS trial pravastatin treatment resulted in an
R for CHD of 0.50 (95% CI 0.38 to 0.68) (Table 5). Thus,
n the present genetic study of the CARE trial absolute risk
eduction by pravastatin was 4.89% (95% CI 1.82% to 7.97%)
Table 6) for carriers of the 719Arg risk allele and 1.39% (95%
I1.94% to 4.72%) for noncarriers; when genotype was not
onsidered in the present study of the CARE trial the absolute
isk reduction was 3.47% (95% CI 1.19 to 5.74). In the present
enetic study of the WOSCOPS trial, projected absolute risk
eduction by pravastatin was 5.49% (95% CI 3.52% to 7.46%)
Table 6) for carriers of the 719Arg risk allele and 0.09% (95%
I1.97% to 2.14%) for noncarriers; when genotype was not
onsidered in the present genetic study the absolute risk
eduction was 3.48% (95% CI 2.51 to 5.36).
Because carriers of the KIF6 719Arg allele benefited from
ravastatin treatment in both the CARE and the
OSCOPS trials, we asked if pravastatin benefit differed
etween carriers and noncarriers. We observed a significant
nteraction between genotype and treatment in the
OSCOPS trial (interaction p 0.01) (Table 5) but not in
he CARE trial (p  0.39).
iscussion
e found that the Trp719Arg SNP in KIF6 was associated
ith risk of recurrent MI in the CARE trial and odds of
HD in the WOSCOPS trial, and this association with
bo Arms of the CARE and WOSCOPS Trials
in the Placebo Arms of the CARE and WOSCOPS Trials
Adjusted*
p Value HR 95% CI p Value
0.01 2.07 1.16–3.67 0.01
0.35 1.24 0.86–1.77 0.25
1.00 ref
Adjusted‡
p Value OR 95% CI p Value
0.76 1.19 0.59–2.41 0.62
0.56 1.09 0.78–1.51 0.62
1.00 ref
), history of hypertension, history of diabetes, body mass index (continuous), baseline LDL-C level
2-year age groups) and smoking (current versus noncurrent); all were men. ‡Matched for age and
eline LDL-C level (continuous), and baseline HDL-C level (continuous).Place
CHD
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age (inisk remained significant after correcting for multiple test-
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January 29, 2008:435–43 KIF6 Trp719Arg in the CARE and WOSCOPS Trialsng. Carriers of the KIF6 719Arg risk allele had an adjusted
R of 1.50 for recurrent MI in the CARE trial and an
djusted OR of 1.55 for CHD in the WOSCOPS trial. The
IF6 719Arg risk allele has also been recently shown to be
ssociated with CHD in the ARIC (Atherosclerosis Risk in
ommunities) study (38).
Although the discovery of genetic polymorphisms that
re associated with CHD may aid in the assessment of an
ndividual’s risk of disease, a therapy that specifically
ounteracts the mechanism of action of the deleterious
ffect of Pravastatin on MI and CHD in KIF6 Trp719Arg Subgroups
Table 5 Effect of Pravastatin on MI and CHD in KIF6 Trp719Ar
Study Genotype Treatment
On-Trial
MI* Total*
CARE Arg/Trp Pravastatin 46 619
Placebo 82 636
Arg/Arg  Arg/Trp Pravastatin 64 810
Placebo 98 791
Trp/Trp Pravastatin 39 554
Placebo 44 542
Case* Control
WOSCOPS Arg/Trp Pravastatin 80 339
Placebo 137 341
Arg/Arg  Arg/Trp Pravastatin 108 330
Placebo 172 263
Trp/Trp Pravastatin 81 213
Placebo 104 256
Number of patients. †Adjusted for gender, age (continuous), current versus non-current smoking
aseline LDL-C level (continuous), and baseline HDL-C level (continuous). ‡Case and control subje
Matched for age and smoking and adjusted for history of hypertension, history of diabetes, bo
Interaction between KIF6 genotype and treatment (2-degrees-of-freedom analysis of all 3 genoty
Abbreviations as in Tables 1 to 3.
bsolute Risk and Absolute Risk Reduction of MI in the CARE Triand of CHD in the WOSCOPS Trial: Effect of Pravastatin in KIF6 Trp
Table 6 Absolute Risk and Absolute Risk Reduction of MI in thand of CHD in the WOSCOPS Trial: Effect of Pravastati
Study Genotype Treatment
CARE All Pravastatin
Placebo
Arg/Arg  Arg/Trp Pravastatin
Placebo
Trp/Trp Pravastatin
Placebo
WOSCOPS All Pravastatin
Placebo
Arg/Arg  Arg/Trp Pravastatin
Placebo
Trp/Trp Pravastatin
Placebo
bsolute risk reduction (ARR) was estimated in the CARE trial at 5 years of follow-up using Kapla
RR was projected for the first 4.9 years of follow–up. In the WOSCOPS trial, absolute risk reductio
hereas in the CARE trial the greater ARR in carriers than in noncarriers did not reach statistical signific
AR  absolute risk; other abbreviations as in Tables 1 to 3.ene variant is unlikely to be immediately available.
owever, carriers of the deleterious gene variant might
enefit from aggressive treatment of modifiable CHD
isk factors. And this may be the case for carriers of the
IF6 risk allele: In both the CARE and the WOSCOPS
rials, carriers of the 719Arg allele significantly benefited
rom pravastatin treatment. Among carriers of the KIF6
19Arg allele, pravastatin treatment in the CARE trial
esulted in an absolute risk reduction of 4.9% and a
elative risk reduction of 37% and in the WOSCOPS
e CARE and WOSCOPS Trials
groups in the CARE and WOSCOPS Trials
Unadjusted Adjusted†
HR 95% CI p Value HR 95% CI p Value
0.56 0.39–0.81 0.002 0.59 0.41–0.85 0.004
1.00 ref 1.00 ref
0.63 0.46–0.86 0.004 0.63 0.46–0.87 0.005
1.00 ref 1.00 ref
0.86 0.56–1.33 0.50 0.80 0.52–1.24 0.32
1.00 ref 1.00
interaction p  0.25 interaction p  0.43¶
interaction p  0.25¶ interaction p  0.39¶
Matched‡ Adjusted§
OR 95% CI p Value OR 95% CI p Value
0.46 0.33–0.64 0.0001 0.45 0.32–0.64 0.0001
1.00 ref 1.00 ref
0.50 0.38–0.67 0.0001 0.50 0.38–0.68 0.0001
1.00 ref 1.00 ref
0.94 0.67–1.33 0.73 0.91 0.64–1.28 0.58
1.00 ref 1.00 ref
interaction p  0.014 interaction p  0.021
interaction p  0.006¶ interaction p  0.011¶
in the WOSCOPS trial), history of hypertension, history of diabetes, body mass index (continuous),
e matched for age (in 2-year age groups) and smoking (current versus noncurrent); all were men.
s index (continuous), baseline LDL-C level (continuous), and baseline HDL-C level (continuous).
elihood ratio test). ¶Interaction between KIF6 carrier status and treatment (likelihood ratio test).
Arg Subgroups
RE Trial
KIF6 Trp719Arg Subgroups
(%) ARR (%) 95% CI p Value
7.37 3.47 1.19–5.74 0.003
0.83
7.60 4.89 1.82–7.97 0.002
2.49
7.00 1.39 1.94–4.72 0.41
8.40
7.06 3.48 2.51–5.36 0.0001
0.54
6.89 5.49 3.52–7.46 0.0001
2.38
7.95 0.09 1.97–2.14 0.99
8.04
r estimates of MI-free survival within subgroups defined by KIF6 genotype. In the WOSCOPS trial,
o pravastatin was significantly greater in carriers of the Arg allele than in noncarriers (p 0.003),in th
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KIF6 Trp719Arg in the CARE and WOSCOPS Trials January 29, 2008:435–43rial resulted in a projected absolute risk reduction of
.5% and a relative risk reduction of 50%.
KIF6 encodes a kinesin, a class of motor proteins involved
n the intracellular transport along microtubules; the cargos
ransported include membrane organelles, protein com-
lexes, and mRNAs (37). Kinesins consist of a conserved
otor domain that propels the kinesin along microtubules
n an ATP dependent manner and a nonconserved tail
omain that binds to its cargo (37). The tail domains
ontain coiled-coil structures that facilitate protein-protein
nteractions (39), and the KIF6 tail domain contains an
lpha-helical region that is predicted by the COILS pro-
ram to form a coiled-coil structure (40). The Trp719Arg
olymorphism is in this predicted coiled-coil structure;
herefore, the Trp719Arg polymorphism, a nonconservative
mino acid change that replaces a nonpolar residue with a
asic residue, might affect the cargo binding of the kinesin
ncoded by KIF6. Several kinesins have been implicated in
he pathogenesis of chronic diseases, such as neurodegen-
rative diseases, type 2 diabetes, and Alzheimer’s disease
41); however, the role of KIF6 and the Trp719Arg SNP in
ardiovascular disease remains to be elucidated.
Of the 10 polymorphisms previously reported to be
ssociated with cardiovascular disease, only the THBS4
la387Pro SNP (9) was associated with recurrent MI in the
ARE trial, and the risk allele in the CARE trial was the
ame as the previously reported risk allele. Although this
NP was not significantly associated with CHD in the
OSCOPS trial, the OR for CHD was higher in carriers
f the THBS4 387Pro allele than in noncarriers.
tudy limitations. One limitation of the present study is
hat only a small number of women were enrolled in the
ARE trial and none were enrolled in the WOSCOPS
rial; therefore, the association of KIF6 Trp719Arg with
ardiovascular risk should be investigated in cohorts that are
dequately powered for analysis in women. Additional
imitations are that the end points and entry criteria of the
ARE and WOSCOPS trials differed and that for 4 of the
0 polymorphisms previously reported in multiple studies to
e associated with cardiovascular disease (in ACE, APOE,
nd AGTR1), power to detect association was 60%.
inally, because KIF6 was not an a priori candidate gene for
ardiovascular disease, the role of kinesin-like protein 6 and
he Trp719Arg polymorphism in the pathogenesis of car-
iovascular disease remains to be determined in future
tudies.
Of the 35 polymorphisms tested, only the KIF6 719Arg
llele was associated with both MI in the CARE trial and
HD in the WOSCOPS trial. In both the CARE and the
OSCOPS trials, carriers of the 719Arg allele received
ignificant and substantial absolute risk reduction from
ravastatin treatment.
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APPENDIX
or supplemental procedure descriptions and a table, please see the online
ersion of this article.
